1-8 of 8
Tom Menzies
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Impact of Lymphocyte Composition in the Stem Cell Harvest on Blood Lymphocytes 1-2 Weeks Post-Autologous Stem Cell Transplant for Newly Diagnosed Myeloma

Benjamin Dimbleby, Tatiana Zhelezniakova, Alex G Richter, Charlotte Pawlyn, John R Jones, Matthew W Jenner, David Cairns, Tom Menzies, Walter Martin Gregory, Martin F. Kaiser, Gordon Cook, Roger G Owen, Graham Jackson, Faith E Davies, Gareth J. Morgan, Mark T Drayson
Journal: Blood
Blood (2022) 140 (Supplement 1): 4299–4300.
https://doi.org/10.1182/blood-2022-169774
Published: 2022
Journal Articles

Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial

John R Jones, David Cairns, Tom Menzies, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Matthew W Jenner, Martin F. Kaiser, Rebecca Mottram, Mark T Drayson, Walter Martin Gregory, Roger G Owen, Kevin Boyd, Gordon Cook, Graham Jackson, Gareth J. Morgan
Journal: Blood
Blood (2022) 140 (Supplement 1): 1823–1825.
https://doi.org/10.1182/blood-2022-168723
Published: 2022
Journal Articles

The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma

Mohamed Shahin, Charlotte Pawlyn, Niels Weinhold, Timothy Cody Ashby, Brian A. Walker, Christopher P. Wardell, David Cairns, Tom Menzies, Walter Martin Gregory, Martin F. Kaiser, Gordon Cook, Mark T Drayson, Roger G Owen, Graham Jackson, Faith E Davies, Gareth J. Morgan, John R Jones
Journal: Blood
Blood (2022) 140 (Supplement 1): 4232–4233.
https://doi.org/10.1182/blood-2022-169628
Published: 2022
Journal Articles

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

Charlotte Pawlyn, Tom Menzies, Faith E Davies, Ruth M. de Tute, Rowena Henderson, Gordon Cook, Matthew W Jenner, John R Jones, Martin F. Kaiser, Mark T Drayson, Roger G Owen, David Cairns, Gareth J. Morgan, Graham Jackson
Journal: Blood
Blood (2022) 140 (Supplement 1): 1371–1372.
https://doi.org/10.1182/blood-2022-165376
Published: 2022
Journal Articles

Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients

Charlotte Pawlyn, Faith E Davies, Tom Menzies, Rowena Henderson, Gordon Cook, Matthew W Jenner, John R Jones, Martin F. Kaiser, Roger G Owen, Mark T Drayson, David Cairns, Gareth J. Morgan, Graham Jackson
Journal: Blood
Blood (2021) 138 (Supplement 1): 2907.
https://doi.org/10.1182/blood-2021-151102
Published: 2021
Journal Articles

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Hannah Victoria Giles, Mark T Drayson, Nicola Wright, Gordon Cook, Faith E. Davies, Gareth J Morgan, Ruth M. de Tute, Roger G Owen, David Cairns, Anna Hockaday, Tom Menzies, Martin F. Kaiser, Charlotte Pawlyn, Graham Jackson, Guy Pratt
Journal: Blood
Blood (2021) 138 (Supplement 1): 820.
https://doi.org/10.1182/blood-2021-150479
Published: 2021
Journal Articles

The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Tom Menzies, Faith E. Davies, Ritika Rana, Jennifer Pinney, Gordon Cook, MD, Walter Martin Gregory, PhD, Matthew W Jenner, John R Jones, MD, Martin F. Kaiser, MD FRCP, FRCPath, Roger G Owen, MD, Gareth Morgan, MD PhD, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, David Cairns, MSc, PhD, Mark T Drayson, MB ChB, PhD FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–43.
https://doi.org/10.1182/blood-2020-139238
Published: 2020
Journal Articles

Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma

Jessica Caro, MD, David Cairns, MSc, PhD, Tom Menzies, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Eileen M Boyle, MD MSc, Gareth Morgan, MD PhD, Gordon Cook, MB ChB, PhD, Martin F. Kaiser, MD FRCP, FRCPath, Roger G Owen, MD, Walter M Gregory, PhD, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, Brian Walker, PhD, Jennifer LJ Heaney, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Faith E. Davies
Journal: Blood
Blood (2020) 136 (Supplement 1): 6.
https://doi.org/10.1182/blood-2020-133516
Published: 2020